Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Burwell Cautions Against Changing FDA Standards, Recommends Cybersecurity Investment

Executive Summary

As one potential candidate for FDA commissioner has called for dismissing efficacy requirements to approve products, Burwell, soon before relinquishing her role as HHS secretary, told reporters that safety trials are insufficient to prove true safety and that her successor at HHS should prioritize cybersecurity.

Advertisement

Related Content

Trump Meets With Two US FDA Commissioner Candidates; Third Still Lurking

Topics

Advertisement
UsernamePublicRestriction

Register

MT104346

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel